An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension-Reference-Cited by-同舟云学术

An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension

Published:2022-01 Issue:1 Volume:12 Page:
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Simon Marc A.¹,Hanrott Kate²,Budd David C.²,Torres Fernando³,Grünig Ekkehard⁴,Escribano‐Subias Pilar⁵,Meseguer Manuel L.⁶,Halank Michael⁷,Opitz Christian⁸⁹,Hall David A.²,Hewens Deborah²,Powley William M.²,Siederer Sarah²,Bayliffe Andrew²¹⁰,Lazaar Aili L.¹¹,Cahn Anthony²,Rosenkranz Stephan¹²

Affiliation:

1. Division of Cardiology, Department of Medicine University of California San Francisco California USA

2. Research and Development, Medicines Research Centre GlaxoSmithKline plc. Stevenage UK

3. UT Southwestern Medical Center Dallas Texas USA

4. Centre for Pulmonary Hypertension Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital Heidelberg Germany

5. CIBER‐CV Cardiology Department, Pulmonary Hypertension Unit Hospital Universitario 12 de Octubre Madrid Spain

6. Lung Transplant and Pulmonary Vascular Diseases Department Hospital Universitari Vall d'Hebron Barcelona Spain

7. Department of Internal Medicine I University Hospital Carl Gustav Carus Dresden Germany

8. Department of Cardiology DRK Kliniken Berlin Germany

9. Department of Cardiology, University Heart Center Berlin Charité University Medicine Berlin Germany

10. Marengo Therapeutics and Apple Tree Partners Cambridge Massachusetts USA

11. Discovery Medicine, Clinical Pharmacology and Experimental Medicine GlaxoSmithKline plc. Collegeville Pennsylvania USA

12. Department III of Internal Medicine, Cologne Cardiovascular Research Center (CCRC) Cologne University Heart Center Cologne Germany

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pul2.12024

Reference34 articles.

1. Pulmonary Arterial Hypertension

2. The Role of the Renin‐Angiotensin‐Aldosterone System in the Pathobiology of Pulmonary Arterial Hypertension (2013 Grover Conference Series)

3. Molecular Mechanisms of Pulmonary Arterial Remodeling

4. Pulmonary Vascular Distensibility Predicts Pulmonary Hypertension Severity, Exercise Capacity, and Survival in Heart Failure

5. Guía ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensión pulmonar

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Angiotensin-Converting Enzyme 2 (ACE2) Signaling in Pulmonary Arterial Hypertension: Underpinning Mechanisms and Potential Targeting Strategies;International Journal of Molecular Sciences;2023-12-13

2. A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells;Frontiers in Immunology;2023-06-13

3. Advances in the discovery of drugs that treat pulmonary arterial hypertension;Expert Opinion on Drug Discovery;2023-04-03

4. New Drugs and Therapies in Pulmonary Arterial Hypertension;International Journal of Molecular Sciences;2023-03-19

5. Renin–angiotensin–aldosterone system inhibitors. New and old approaches;Angiotensin;2023